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A B S T R A C T
Background
People admitted to intensive care units and those with chronic health care problems often require long-term vascular access. Central
venous access devices (CVADs) are used for administering intravenous medications and blood sampling. CVADs are covered with a
dressing and secured with an adhesive or adhesive tape to protect them from infection and reduce movement. Dressings are changed
when they become soiled with blood or start to come away from the skin. Repeated removal and application of dressings can cause
damage to the skin. The skin is an important barrier that protects the body against infection. Less frequent dressing changes may reduce
skin damage, but it is unclear whether this practice affects the frequency of catheter-related infections.
Objectives
To assess the effect of the frequency of CVAD dressing changes on the incidence of catheter-related infections and other outcomes
including pain and skin damage.
Search methods
In June 2015we searched:TheCochraneWounds SpecialisedRegister; TheCochraneCentral Register ofControlledTrials (CENTRAL)
(The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid EMBASE and
EBSCO CINAHL. We also searched clinical trials registries for registered trials. There were no restrictions with respect to language,
date of publication or study setting.
Selection criteria
All randomised controlled trials (RCTs) evaluating the effect of the frequency of CVAD dressing changes on the incidence of catheter-
related infections on all patients in any healthcare setting.
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Data collection and analysis
We used standard Cochrane review methodology. Two review authors independently assessed studies for inclusion, performed risk of
bias assessment and data extraction. We undertook meta-analysis where appropriate or otherwise synthesised data descriptively when
heterogeneous.
Main results
We included five RCTs (2277 participants) that compared different frequencies of CVAD dressing changes. The studies were all
conducted in Europe and published between 1995 and 2009. Participants were recruited from the intensive care and cancer care
departments of one children’s and four adult hospitals. The studies used a variety of transparent dressings and compared a longer
interval between dressing changes (5 to15 days; intervention) with a shorter interval between changes (2 to 5 days; control). In each
study participants were followed up until the CVAD was removed or until discharge from ICU or hospital.
Confirmed catheter-related bloodstream infection (CRBSI)
One trial randomised 995 people receiving central venous catheters to a longer or shorter interval between dressing changes and
measured CRBSI. It is unclear whether there is a difference in the risk of CRBSI between people having long or short intervals between
dressing changes (RR 1.42, 95% confidence interval (CI) 0.40 to 4.98) (low quality evidence).
Suspected catheter-related bloodstream infection
Two trials randomised a total of 151 participants to longer or shorter dressing intervals and measured suspected CRBSI. It is unclear
whether there is a difference in the risk of suspected CRBSI between people having long or short intervals between dressing changes
(RR 0.70, 95% CI 0.23 to 2.10) (low quality evidence).
All cause mortality
Three trials randomised a total of 896 participants to longer or shorter dressing intervals and measured all cause mortality. It is unclear
whether there is a difference in the risk of death from any cause between people having long or short intervals between dressing changes
(RR 1.06, 95% CI 0.90 to 1.25) (low quality evidence).
Catheter-site infection
Two trials randomised a total of 371 participants to longer or shorter dressing intervals and measured catheter-site infection. It is unclear
whether there is a difference in risk of catheter-site infection between people having long or short intervals between dressing changes
(RR 1.07, 95% CI 0.71 to 1.63) (low quality evidence).
Skin damage
One small trial (112 children) and three trials (1475 adults) measured skin damage. There was very low quality evidence for the effect
of long intervals between dressing changes on skin damage compared with short intervals (children: RR of scoring ≥ 2 on the skin
damage scale 0.33, 95% CI 0.16 to 0.68; data for adults not pooled).
Pain
Two studies involving 193 participants measured pain. It is unclear if there is a difference between long and short interval dressing
changes on pain during dressing removal (RR 0.80, 95% CI 0.46 to 1.38) (low quality evidence).
Authors’ conclusions
The best available evidence is currently inconclusive regarding whether longer intervals between CVAD dressing changes are associated
with more or less catheter-related infection, mortality or pain than shorter intervals.
P L A I N L A N G U A G E S U M M A R Y
How often should dressings on central venous access devices (CVADs) be changed to reduce catheter-related infection?
Background
A central venous access device (CVAD, also known as a central venous catheter) is a hollow tube that is placed in a large vein with the
tip sitting near the heart. CVADs allow medications, fluids and blood products to be given straight into the bloodstream and allow
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blood samples to be taken for analysis. One of the negative consequences of a CVAD can be an infection of the blood stream which is
called catheter-related bloodstream infection or CRBSI which can be serious and even life-threatening. Some CVADs can stay in place
for weeks, months or years. Most patients admitted to an intensive care unit will have a CVAD inserted and patients with poor veins
or requiring long-term treatment will be offered a CVAD. Dressings are placed over the insertion site of the catheter where it enters the
vein, usually in the chest, neck or arm, to protect the surrounding skin. Dressings help prevent infections from starting and they stop
the CVAD from moving around. Dressings are changed when they become dirty or they start to fall off. Frequent dressing changes can
cause damage to the surrounding skin, so patients may experience pain or skin damage when the dressing is removed. Changing the
dressing frequently is also expensive.
We wanted to see if there were any advantages or disadvantages to longer or shorter time intervals between CVAD dressing changes.
Some hospitals or healthcare facilities recommend changing dressings every few days, while others keep dressings in place for longer.
Review question
We reviewed the available evidence about the effect of different time intervals between dressing changes for CVADs and whether they
had an effect on the risk of CRBSI and other complications. We found five studies that provided information for our review.
Study characteristics
The five studies that were included in the review were published between 1995 and 2009 and involved a total of 2277 participants. Four
countries were represented (two studies from France and one each from Italy, Sweden, and the Czech Republic). One study involved
children and the remaining four trials included only adults. Four of the studies included cancer patients and one included patients in
an intensive care unit.
We classified the time intervals between dressing changes as short (2 - 5 days) in the more frequently changed dressings group and long
(5-15 days) in the less frequently changed group. All studies used transparent dressings made of synthetic materials and two studies used
gauze (a fabric dressing that does not stick to the skin) secured with tape when skin was damaged. CVAD dressings were monitored on
a daily basis in all trials and participants were followed up at least until the CVAD was removed or until discharge. In one study, the
manufacturer provided one of the products, but had no influence in the design or how the results were analysed and reported.
Key results
The current evidence leaves us uncertain whether the frequency of dressing changes for CVADs influences risk of CRBSI or death. Of
particular interest to patients are problems that may be associated with the dressing themselves, such as pain when they are removed
and the skin damage that the dressing may cause. We found no clear evidence that pain, which was assessed daily, was affected by the
frequency of dressing changes.
Quality of evidence
The quality of the evidence was very low or low. We downgraded quality because of small and few studies, poor study designs and
differences in results between the studies. Better designed studies are still needed to show whether longer interval or shorter intervals
between dressing changes are more effective in preventing catheter related infections, mortality, skin damage, dressing removal pain,
quality of life and cost.
This plain language summary is up-to-date as of 10 June 2015.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: patients with a central venous access device
Setting: Hospital or community settings in Europe
Intervention: longer intervals between dressing changes (5 - 15 days) (intervention)
Comparison: shorter intervals between dressing changes (2 - 5 days) (control)
Outcomes Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality of the evidence
(GRADE)
What happens
Without longer interval
(5 - 15 days)
With longer interval (5 -
15 days)
Difference
Catheter-related blood
stream infection (CRBSI)
assessed with: as defined
by CDC (2002)
follow up: median 11
days
of participants: 995
(1 RCT)
RR 1.42
(0.40 to 4.98)
Study population ⊕⊕©©
LOW 12
Longer intervals between
dressing changes may
have little or no effect
on catheter-related blood
stream infection
8 per 1000 12 per 1000
(3 to 41)
4 more per 1000
(5 fewer to 33 more)
All-cause mortality
assessed with: unclear
follow up: range 48 hours
after discharge from ICU
to 120 days
of participants: 896
(3 RCTs)
RR 1.06
(0.90 to 1.25)
Study population ⊕⊕©©
LOW 34
Longer intervals between
dressing changes proba-
bly have little or no effect
on death from any cause
354 per 1000 375 per 1000
(318 to 442)
21 more per 1000
(35 fewer to 88 more)
Skin damage
of participants: 1587
(4 RCTs)
Follow up: unclear
Not estimable Skin damage was reported in four studies. Two provided data but their results
were not combined due to inconsistency of size and direction of the effects.
One study in children found less skin damage in the longer interval group (8/
56) compared with the shorter interval group (24/56). Rates of skin damage in
one study in adults were similar (7/39 in longer interval versus 6/42 in shorter
interval).9
⊕©©©
VERY LOW 567
It is uncertain whether
longer (compared with
shorter) intervals be-
tween dressing changes
reduce skin damage
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Pain
of participants: 193
(2 RCTs)
Follow up: unclear
RR 0.80
(0.46 to 1.38)
Study population ⊕⊕©©
LOW 178
It is uncertain whether
longer (compared with
shorter) intervals be-
tween dressing changes
affect pain on dressing re-
moval
347 per 1000 278 per 1000
(160 to 479)
69 fewer per 1000
(187 fewer to 132 more)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded for risk of bias due to lack of blinding of participants and personnel and for a probable unit of analysis error (individual
participants randomised but numbers of infections reported)
2 Downgraded for serious imprecision: result consistent with a reduction in CRBSI or an almost 5 fold increase
3 Downgraded for risk of bias due to lack of blinding of participants and personnel
4 Downgraded for imprecision: result consistent with a 10% reduction in mortality or a 25% increase
5 Downgraded twice for serious risk of bias: risk of performance bias due to lack of blinding of participants and personnel; different
dressings were used in response to skin damage
6 Downgraded for inconsistency: experimental and control groups were different between studies and frequency of dressing changes
overlapped between longer and shorter groups
7 Downgraded for imprecision
8 Downgraded for risk of bias: blinding of outcome assessment not described
9 Data from two additional RCTs could not be extracted and used within the analysis. One study presented toxicity on a 5-point scale and
reported no differences between groups. We are unable to use the data from the fourth study due to the 2 x 2 factorial design.
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B A C K G R O U N D
See Appendix 1 for glossary of terms.
Description of the condition
Central venous access devices (CVADs), also commonly called
central venous catheters, are inserted when a patient requires ve-
nous access over an extended period of time. These devices are
commonly used in patients admitted to intensive care units, for
patients with oncological and haematological malignancies and
other chronic health problems. CVADs are used to administer
intravenous drugs including chemotherapy and immunosuppres-
sion, fluids, blood products, total parenteral nutrition, and for
blood sampling.
The external portion of the CVAD can be partially tunnelled un-
der the skin or non-tunnelled. Non-tunnelled catheters are those
where the insertion site is directly above the entry into the vein
(CNSA 2007); they are for short-term use and can be sited using
the jugular, subclavian or femoral veins (Hayden 2005). Periph-
erally inserted central catheters (PICCs) are also non-tunnelled
and are inserted into the central circulation usually from a periph-
eral vein in the upper arm - they can remain in place for months
(Gabriel 2005; Hayden 2005; RNAO 2005). Tunnelled CVADs
are surgically implanted with a section of the catheter positioned
in a subcutaneous tunnel between the entry site, which heals over,
to the vein and the skin exit site (CNSA 2007), and are typically
placed into the superior vena cava.
CVADs are covered with a dressing and secured with a separate se-
curement device or skin adhesive, such as tape or transparent adhe-
sive film, to prevent infection andmovement (Hunt 1997;Wilson
2006 and Elkabir 2001; Rippon 2007, respectively). Newer prod-
ucts are available that combine both the dressing and securement
function. The repeated application and removal of adhesives or
adhesive tapes and dressings from the same site can cause damage
to the skin by skin stripping, that is the removal of the superfi-
cial stratum corneum, which can cause development of inflam-
matory skin reactions, oedema and soreness (Cutting 2008).The
entry and exit sites of CVADs are inspected visually daily for signs
of infection, and this may require removal of the dressing. Dress-
ings are replaced if they become loose, soiled or wet. Frequent
dressing changes can impact upon the skin integrity surrounding
the CVAD entry and exit sites. If skin integrity is compromised,
rates of catheter-related infection (CRI) including CRBSI may be
affected.
Description of the intervention
The intervention of interest in this review is the frequency of dress-
ing changes. Adhesives or adhesive tapes are designed to bond to
the skin under a variety of conditions, such as flexure, changing
temperatures, in the presence of perspiration and external mois-
ture, but should also be easy to peel off in order to ensure minimal
discomfort and trauma (Karwoski 2004). Choice of dressings and
frequency of changes depends upon clinical practice protocols,
and patient and clinician preferences (CNSA 2007; Gillies 2003;
O’Grady 2011). The general consensus is for gauze dressings to be
changed every 48 hours (CNSA 2007; Hadaway 2003; O’Grady
2011; Rosenthal 2003; RNAO 2005), and transparent semi-per-
meable dressings every seven days, or earlier if the integrity of the
dressings is compromised or there is blood underneath the dress-
ing (Camp-Sorrell 2004; CNSA 2007; Loveday 2014; Hadaway
2003; INS 2011; IVNNZ 2012; O’Grady 2011; Rosenthal 2003;
RNAO 2005).
How the intervention might work
CVADs are commonly used in patients admitted to intensive
care and those diagnosed with chronic diseases and cancer. These
patients are often immunocompromised and healing processes
are diminished due to their disease or treatment (Cutting 2008;
Lotti 1998). The skin provides protection as a barrier to infec-
tion (Tortura 2000), so maintaining skin integrity is particularly
important for these patients. Chemotherapy and radiation regi-
mens can cause adverse skin changes (DeSpain 1992; Glean 2001;
Hopewell 1990). Other patients at particular risk of skin dam-
age are older adults, babies and young children who, by nature
of their age, have fragile skin (Hollingworth 2009), and patients
with disease-related factors associatedwith dermatological changes
(Cutting 2008). Constantly removing adhesives or adhesive tapes
to change dressings may further aggravate already damaged skin
(Hollingworth 2009). Thus, reducing the frequency of dressing
changes may reduce skin damage, pain, costs, incidence of skin
colonization and the potential for CRIs. A theoretical risk exists
that transparent dressings increase surface humidity, which may
lead to increased microbial colonisation at the catheter site and so
increase the risk of CRI (Wille 1993). Therefore, prolonging the
interval between dressing changes may increase infection due to
increased skin colonisation underneath the dressing.
Why it is important to do this review
There is a lack of clear evidence concerning the optimal frequency
of dressing changes for CVADs. Clinical guidelines have influ-
enced a general consensus around the timing of dressing changes
for CVADs, but the guidelines themselves are based on limited
evidence. For example, recommendations in the Centers for Dis-
ease Control and Prevention (CDC) guidelines suggest only tun-
nelled CVADs with well-healed sites might not require dressings
(O’Grady 2011), but there is no recommendation about frequency
of changes before sites are healed. Patients diagnosed with cancer
are particularly vulnerable to skin damage because of the treatment
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they receive (Cutting 2008; Lotti 1998). Extending the time be-
tween dressing changesmay reduce the damage and also reduce the
associated costs. However, it remains unclear whether prolonging
the time between changes results in other complications, such as
an increased risk of bloodstream infection. We will examine the
existing research to determine how frequently dressings that are
used to protect CVADs should be changed. We are primarily in-
terested in the incidence of CRI, but will also consider outcomes
such as pain and skin damage.
O B J E C T I V E S
To assess the effect of the frequency of CVAD dressing changes
on the incidence of CRIs and other outcomes including pain and
skin damage.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) evaluating the effect of the
frequency of CVAD dressing changes on the incidence of CRIs.
We excluded studies comparing different dressing products and
studies where the frequency of dressing change was not the only
systematic difference between treatment arms as we required an
explicit focus upon the frequency of changing the same type of
dressing. Cluster-randomised controlled trials, quasi-randomised
trials and cross-over trials were not included in order to minimise
potential bias in accordance with Reeves 2011.
Types of participants
Participants of any age requiring a CVAD in any healthcare or
community setting.
Types of interventions
Trials comparing any frequency of changing the same type of dress-
ings for the securement of a CVAD.
Types of outcome measures
Primary outcomes
• Incidence of confirmed catheter-related bloodstream
infection (CRBSI) defined as bacteraemia or fungaemia in a
patient with an intravascular catheter with at least one positive
blood culture obtained from a peripheral vein, clinical
manifestations of infection (i.e. fever, chills, and/or
hypotension), and no apparent source for the bloodstream
infection except the catheter. One of the following should be
present for a positive diagnosis: a positive semi-quantitative (> 15
colony forming units (CFU)/catheter segment) or quantitative (>
10³ CFU/catheter segment) culture from a catheter segment in
which the same organism (species and antibiogram) is isolated
from the catheter segment and peripheral blood (CDC 2002).
• Incidence of suspected CRBSI, as described by the trial
investigator.
• All-cause mortality.
Secondary outcomes
• Incidence of catheter entry and exit site infection, as
described by the trial investigator.
• Skin damage, using an assessment tool (such as the Eastern
Cooperative Oncology Group Common Toxicity Criteria for
Skin (ECOG 2007; see Appendix 2).
• Pain, using any validated measure or scale described by the
trial investigator.
• Quality of life, using any validated measure or scale
described by the trial investigator.
• Cost.
Search methods for identification of studies
Electronic searches
In June 2015 we searched the following electronic databases to
identify reports of relevant randomised clinical trials:
• The Cochrane Wounds Specialised Register (searched 11
June 2015);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2015, Issue 6);
• Ovid MEDLINE (1946 to 10 June 2015);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (searched 10 June 2015);
• Ovid EMBASE (1974 to 10 June 2015);
• EBSCO CINAHL (1982 to 11 June 2015).
The search strategies used can be found in Appendix 3. We com-
bined theOvidMEDLINE searchwith theCochrane Highly Sen-
sitive Search Strategy for identifying randomised trials in MED-
LINE: sensitivity- and precision-maximising version (2008 revi-
sion) (Lefebvre 2011). We combined the EMBASE search with
the Ovid EMBASE filter developed by the UK Cochrane Centre
(Lefebvre 2011). We combined the CINAHL search with the trial
filter developedby the Scottish IntercollegiateGuidelinesNetwork
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(SIGN 2011). There were no restrictions with respect to language,
date of publication or study setting.
In July 2014 we searched the following clinical trials registers:
• Australian and New Zealand Clinical Trials Register (
www.anzctr.org.au)
• ClinicalTrials.gov (www.clinicaltrials.gov/)
• Current Controlled Trials (www.controlled-trials.com/)
• World Health Organization (WHO) International Clinical
Trials Registry Platform (http://apps.who.int/trialsearch/)
• European Union Clinical Trials Register (
www.clinicaltrialsregister.eu/)
Searching other resources
We searched reference lists of all retrieved and relevant publications
identified by these strategies for further studies not identified by
the methods outlined above.
Data collection and analysis
Selection of studies
Two review authors (NG and JW) acting independently located
potentially eligible studies by screening titles and abstracts from
the search. We obtained full copies of potentially eligible stud-
ies and acting independently, decided on inclusion based on the
predefined inclusion and exclusion criteria. We have listed the
excluded studies with reasons for their exclusion (Characteristics
of excluded studies). Disagreements were resolved by discussion
among the review authors.
Data extraction and management
We extracted data from eligible studies using a data extraction
sheet. This summary contained baseline characteristics of study
and control group participants and included the number of par-
ticipants, age, gender, disease, treatment, reason for insertion of
CVAD, method of insertion, profession of inserter (doctor, radio-
grapher or nurse), anatomical location of insertion, type of CVAD,
number of lumens on the CVAD, dwell time of the CVAD, dress-
ing protocol, deviation from planned dressing day and reason,
number of dressing changes during dwell time of the CVAD,
known allergies to dressings, skin complexion and known history
of or current positive blood cultures. We extracted the criteria for
patient inclusion and exclusion, a description of the intervention
and the number of patients randomised to each intervention. We
recorded the healthcare settings in which the interventions were
performed. In addition, we extracted the duration of follow-up
and numbers lost to follow-up as well as outcomes.
When more than one publication arose from a study, we extracted
data from all relevant publications, but did not duplicate data
in analyses. Two review authors (NG and JW) extracted all data
independently. Disagreements were resolved by discussion. If this
had not resulted in consensus, the third review author’s opinion
would have been decisive (RC).
Assessment of risk of bias in included studies
Two review authors (NG and JW) independently assessed each
eligible study using the Cochrane tool for assessing risk of bias
(Higgins 2011). This tool addresses six specific domains, namely
sequence generation, allocation concealment, blinding, incom-
plete outcome data, selective outcome reporting and other issues
(for example, extreme baseline imbalance; see Appendix 4 for de-
tails of criteria on which the judgements were based). We assessed
blinding and completeness of outcome data for each outcome sep-
arately. We completed a ’Risk of bias’ table for each eligible study.
Disagreements were discussed in a consensus meeting.
The assessment of risk of bias is presented using a ’Risk of bias’
summary figure, which includes all the judgements in a cross-tab-
ulation of study by entry. This display of internal validity indicates
the confidence the reader may give to the results of the particular
studies.
Measures of treatment effect
Event rates for dichotomous outcomes are presented as risk ratios
(RR) with 95% confidence intervals (CI). There were no contin-
uous outcomes or time to event outcomes.
Unit of analysis issues
The unit of analysis was individual patients with a CVAD in situ.
All five studies included in the review randomised the patients
and not their CVAD, but three studies presented some results per
CVAD or per dressing and we contacted the authors to obtain the
results per patient (Engervall 1995; Rasero 2000; Timsit 2009).
Timsit 2009 was the only paper to present CRBSI, our primary
outcome. A decision was made to present the data per catheter
rather than per patient for this one outcome in the absence of
any other data. Cross-over and cluster-randomised trials were not
included.
Dealing with missing data
If data were missing from the published trial reports, we made
attempts to contact the study authors to complete the informa-
tion necessary for the analysis and ’Risk of bias’ assessment. We
did not impute data if the missing data were not obtained after
several attempts to contact the author. If no further information
was provided we used an available case analysis. We addressed the
potential impact of missing data on the findings of the review in
the Discussion.
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Assessment of heterogeneity
We included trials in a meta-analysis if the study population and
the interventions studied were sufficiently similar. We assessed sta-
tistical heterogeneity using the I² statistic (Higgins 2003), which
examines the percentage of total variance across studies due to het-
erogeneity rather than chance. Values of I² under 25% indicate a
low level of heterogeneity and justify use of a fixed-effect model for
meta-analysis. Values of I² between 25% and 75% are considered
moderate and a random-effects model can be used. Values of I²
higher than 75% indicate high levels of heterogeneity and pooling
should not be undertaken.
Assessment of reporting biases
We reported each outcome separately. We were not able to use
funnel plots to assess reporting biases, as an insufficient number
of studies was included.
Data synthesis
If the studies were sufficiently similar we pooled them using a
fixed-effect model for values of I² under 25%. In the event of
moderate heterogeneity we employed a random-effects model. If
the studies were statistically heterogenous (I²≥ 75%)we produced
a qualitative summary (O’Rourke 1989).
’Summary of findings’ tables
We have presented the main results of the review in ’Summary of
findings’ (SoF) tables. These tables present key information con-
cerning the quality of the evidence, the magnitude of the effects of
the interventions examined, and the sum of the available data for
the main outcomes (Schünemann 2011a). The SoF tables also in-
clude an overall grading of the evidence related to each of themain
outcomes using the GRADE (Grades of Recommendation, As-
sessment, Development and Evaluation) approach. The GRADE
approach defines the quality of a body of evidence with regard to
the extent to which one can be confident that an estimate of effect
or association is close to the true quantity of specific interest. The
quality of a body of evidence involves consideration of within-trial
risk of bias (methodological quality), directness of evidence, het-
erogeneity, precision of effect estimates and risk of publication bias
(Schünemann 2011b). The following outcomes, which we believe
to be the most important both clinically and to the consumer, are
presented in the SoF tables:
• CRBSI;
• all-cause mortality;
• skin damage;
• pain.
Subgroup analysis and investigation of heterogeneity
We did not plan any subgroup analyses. We planned to investigate
heterogeneity using sensitivity analysis (see below).
Sensitivity analysis
Too few studies were included in the meta-analyses to conduct
a sensitivity analysis. We were not able to explore the effect of
concealment of allocation (adequate versus not reported, unclear
or not undertaken).
R E S U L T S
Description of studies
See Characteristics of included studies, Characteristics of excluded
studies and Characteristics of studies awaiting classification.
In this review comparisons were grouped by longer duration be-
tween dressing changes versus shorter duration between dressing
changes with the shorter duration treated as the control group as
this is considered standard practice by the trial authors.
Results of the search
The electronic search identified 471 titles. Of these, 453 were ex-
cluded by an examination of the titles and abstracts: two were du-
plicates; 136 were excluded because they did not contain informa-
tion about CVADs; and 315 compared different dressings or were
on other topics. The remaining 18 full texts were retrieved and
reviewed. Of these, 10 did not meet the inclusion criteria and were
excluded (see Characteristics of excluded studies). Five published
RCTsmet the inclusion criteria (Benhamou 2002; Engervall 1995;
Rasero 2000; Timsit 2009; Vokurka 2009), and three were supple-
mentary references to included papers (see Criteria for considering
studies for this review and Characteristics of included studies and
Figure 1).
9Frequency of dressing changes for central venous access devices on catheter-related infections (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Flow diagram of included and excluded studies
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A search of the clinical trials registers did not identify any ad-
ditional trials. Only one study had been pre-registered (Timsit
2009).
The reference lists of all retrieved and relevant publications were
searched. One study was considered to be relevant but was not
available through library resources (Fessard 1994). Attempts to
contact the author and locate the journal are continuing.
Included studies
Types of patients
The five trials involved a total of 2277 participants, with the to-
tals in individual trials ranging from 32 to 1653. One study in-
volved children (Benhamou 2002), and the remaining four in-
cluded adults only (Engervall 1995; Rasero 2000; Timsit 2009;
Vokurka 2009). Two studies were set in a bone marrow transplant
unit (Benhamou 2002; Rasero 2000), two studies consisted of
patients undergoing treatment for a haematological malignancy
(Engervall 1995; Vokurka 2009), and one study recruited patients
receiving treatment in intensive care (Timsit 2009). Four countries
were represented (two studies fromFrance and one each from Italy,
Sweden, and the Czech Republic). All studies were conducted in
acute in-patient settings. Patients were excluded from the studies
if their skin was already damaged (Benhamou 2002; Rasero 2000;
Vokurka 2009); were having treatment that would make them
more susceptible to skin damage, such as the chemotherapeutic
drug busulphan-thiotepa (Benhamou 2002), or radiation to the
chest (Vokurka 2009); or if they had allergies to polyurethane
dressings (Rasero 2000; Timsit 2009; Vokurka 2009), chlorhexi-
dine (Timsit 2009), or disinfectant (Vokurka 2009).
Types of interventions
Time frames for dressing changes varied between 2 and15 days.
One study planned to compare 15-day and 4-day dressing changes
for tunnelled catheters (Benhamou 2002). CVAD dressings were
monitored on a daily basis in all trials and patients were followed
up until the CVAD was removed or until discharge as a mini-
mum. However, in this study there were a large number of proto-
col violations, that is, dressings were changed on days other than
the day indicated in the protocol. In the 15-day group, only 67
(17%) of the 365 dressing were changed on day 15 and, in the
4-day group, 516 (76%) of the 678 dressings were changed on
the correct day. This meant that dressing changes in the 15-day
group were actually changed, on average, every eight days and, in
the 4-day group, every four days. Reasons for the protocol viola-
tions included soiled and dislodged dressings and problems with
the catheter that required the dressing to be removed. Two stud-
ies compared once versus twice-weekly dressing changes for tun-
nelled CVADs (Engervall 1995; Timsit 2009), two studies com-
pared once versus twice-weekly dressing changes for non-tunnelled
CVADs (Timsit 2009; Vokurka 2009), and one study compared
5-day versus 10-day dressing changes for tunnelled CVADs and
2-day versus 5-day dressing changes for non-tunnelled CVADs
(Rasero 2000). Again however, reflecting the reality of pragmatic
research in clinical settings,many of the dressingswere not changed
according to the group schedule. In the tunnelled CVAD 10-day
group 9.6% were not changed on the correct day, while in the
tunnelled CVAD 5-day group the proportion was 8.0%; in addi-
tion 6.8% of non-tunnelled CVCs in the 5-day group were not
changed as scheduled and in the non-tunnelled CVC 2-day group
the rate was 12.5%.
The dressings were applied under controlled conditions in all
groups. Three studies stated that nurses were responsible for
the dressing changes (Benhamou 2002; Engervall 1995; Rasero
2000). Four studies used Tegaderm (3M, St Paul, USA) dress-
ings (Benhamou 2002; Engervall 1995; Rasero 2000; Timsit
2009), and one study used Bioclusive (Johnson and Johnson,
New Jersey, USA; Vokurka 2009). One study used chlorhexidine
gluconate-impregnated sponges (Biopatch, Ethicon, New Jersey,
USA) around the entry or exit site of the CVAD under the dress-
ings (Timsit 2009).
Three studies used the same dressings throughout the period of
observation. Two studies used different dressings that depended
upon skin damage. One study used a Tegaderm (3M) covering a
sterile gauze for grade 0 to 1 skin damage (48/56; 85% in the 15-
day group and 32/56; 57% in the 4-day group), sterile gauze with
Mefix for grade 2 to 3 skin damage (7/56; 13% in the 15-day group
and 23/56; 41% in the 4-day group) and sterile gauze with tape for
grade 4 skin damage (1/56; 2% in both the 15- and 4-day groups;
Benhamou 2002). The other study used a Tegaderm (3M) for
undamaged skin or an exit site with mild erythema, but if the exit
site had extensive erythema or other signs of local infection then
the dressings were changed daily using a gauze dressing moistened
with 10% ethanol with aluminium acetotartrate 10% until the
erythema had disappeared, at which point the patient was returned
to the allocated group (Engervall 1995). Patients in the once-
weekly group had more extra dressings due to erythema compared
to the twice-weekly group (3%; 0 to 91% once-weekly group;
0%; 0 to 17% twice-weekly group; P value 0.08 expressed as extra
dressings days per CVAD days).
Skin decontamination varied between the groups. Two studies
used the same antiseptic solution to clean the skin before the in-
sertion of the CVAD and at dressing changes; one study used an
alcohol-based povidone-iodine solution (Timsit 2009); and one
used povidone-iodine solution; whether the antiseptic was alco-
hol-based was unclear (Vokurka 2009). One study used a 0.5%
alcohol based chlorhexidine solution during insertion and at dress-
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ing changes, but changed to aqueous-based povidone-iodine if the
skin became damaged (Benhamou 2002). One study did not de-
scribe skin decontamination that occurred prior to CVAD inser-
tion but used 70% ethanol at dressing changes (Engervall 1995).
One study did not mention which antimicrobial solution was used
for skin decontamination (Rasero 2000).
Types of outcomes
Only one trial used a standard definition for confirmed CRBSI (
Timsit 2009), two trials reported blood culture results (Benhamou
2002; Vokurka 2009), and one study reported blood culture and
CVAD-tip culture results separately (Engervall 1995). Blood cul-
tures were performed on clinical suspicion of infection or deter-
mined by a temperature threshold stipulated by each study au-
thor. Three studies provided information about suspected CRBSI
but these studies used different definitions (Benhamou 2002;
Engervall 1995; Timsit 2009): Benhamou 2002 did not provide
a definition; Engervall 1995 defined suspected CRBSI as not re-
sponding to antibiotics; and Timsit 2009 had an investigator
blinded to the study group review the patient’s case including the
medical chart in order to perform an independent blinded review.
In all five studies, catheter-site infectionwas definedby skin coloni-
sation and additionally in three studies by local signs of catheter-
site infection such as the presence of inflammation, erythema, ten-
derness, swelling or discharge (Benhamou 2002; Engervall 1995;
Timsit 2009). Two studies measured pain: Benhamou 2002 used
categories of none, moderate or severe; and Vokurka 2009 used a
visual analogue score ranging from 0 to 10 (0: no pain, 5: moder-
ate pain, 10: severe pain). No study measured quality of life. Two
studies measured cost (Rasero 2000; Timsit 2009).
In the Timsit 2009 trial, a 2 x 2 factorial design was used, in which
participants were randomised to a 3- or 7-day dressing change
and to a dressing alone or with chlorhexidine gluconate-impreg-
nated sponge (CHGIS). They also combined arterial and central
catheters in their analysis. The authors were contacted and pro-
vided information based on central catheters only and reported
separately for the CHGIS and non-CHGIS groups. For our anal-
ysis we have included only the non-CHGIS group, to maintain
consistency with other trials.
Excluded studies
The Table of Characteristics of excluded studies specifies our rea-
sons for excluding 10 studies. One was a systematic review (Zitella
2003); three studies compared different dressings (Davidson
1986; Hagerstrom 1994; Lucas 1996); one was a study protocol
(Bystricka 2004); one was a letter to the editor commenting on a
study of dressings (Dickerson 1989); in three studies the frequency
of dressing change was not the only systematic difference between
treatment groups (Powell 1985; Samsoondar 1985; Young 1988);
and one was a cluster RCT (Ishizuka 2011).
Risk of bias in included studies
See the ’Risk of bias’ tables in the Characteristics of included
studies section and Figure 2; Figure 3; Table 1 and Table 2.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
Random sequence generation
Three studies used computer-generated lists to generate the allo-
cation sequence (Benhamou 2002; Timsit 2009; Vokurka 2009).
One study used manually mixed envelopes (Engervall 1995). One
study did not describe how the random sequence was generated
(Rasero 2000).
Allocation concealment
Vokurka 2009 used computer software to conceal the allocation
of trial patients into individual groups. We contacted the trialists
of Engervall 1995 who stated that they had used randomisation
envelopes. The other three studies did not describe how the alloca-
tion was concealed (Benhamou 2002; Rasero 2000; Timsit 2009).
Blinding
Blinding of participants and personnel
None of the studies was able to blind participants or staff involved
in direct care from identifying the allocated intervention due to
the nature of the intervention.
Blinding of outcome assessment
Timsit 2009 mentioned blinding of outcome assessment, stating
that staff involved in analysing catheter cultures and reviewing
CRBSI were blinded to the study groups. It was unclear in the
remaining four trials whether outcome assessors were blinded (
Benhamou 2002; Engervall 1995; Rasero 2000; Vokurka 2009).
Incomplete outcome data
A flow chart was provided by Timsit 2009 that included the num-
bers of patients screened, excluded, randomised to each group
and withdrawals and reasons for exclusions from the per-proto-
col analysis. Four studies accounted for all randomised partici-
pants and their withdrawal from each group (Benhamou 2002;
Engervall 1995; Rasero 2000; Vokurka 2009). Two studies re-
ported sample size calculations andused an intention-to-treat anal-
ysis (Benhamou 2002; Timsit 2009). Two studies presented results
per patient (Benhamou 2002; Vokurka 2009). Two studies pre-
sented results per catheter and per patient (Engervall 1995; Timsit
2009). One study presented results per dressing and per patient
(Rasero 2000). Overall, reported attrition rates were low and well
balanced. There was a proportionally higher attrition rate in one
arm of the Timsit 2009 trial, but losses were marginal and unlikely
to have had an impact on outcomes.
Four studies monitored the CVAD sites closely and dressings
were changed if they were loose or soiled (Benhamou 2002;
Rasero 2000; Timsit 2009; Vokurka 2009). This meant that ap-
proximately one-third of the participants had additional dressing
changes that constituted protocol violations. These violationswere
reported in the results.
Selective reporting
A study protocol was available for one study (Timsit 2009). All
other authors provided results for outcomes mentioned in their
published methods section (Benhamou 2002; Engervall 1995;
Rasero 2000; Vokurka 2009).
Other potential sources of bias
Benhamou 2002 andEngervall 1995 varied their dressing protocol
according to the grade of skin damage. The interim analysis in
the Engervall 1995 study showed no statistical significance for the
rates of the primary outcome between groups, so the study was
stopped and the secondary outcomes analysed. Rasero 2000 did
not present baseline data. In one study, themanufacturer provided
one of the products but they had no influence in the design or
how the results were analysed and reported (Timsit 2009).
Effects of interventions
See: Summary of findings for the main comparison Longer
intervals (5-15 days) (intervention) versus shorter intervals (2-5
days) (control) between dressing changes for preventing catheter-
related infection in people with central venous access devices
Primary outcomes
Confirmed catheter-related bloodstream infection (995
central venous catheters)
Only one study (Timsit 2009), that had uncertain risk of bias
for allocation concealment, reported confirmed CRBSI as per our
protocol. There was no clear evidence of a difference between
groups for this outcome (RR 1.42; 95% CI 0.40 to 4.98; Analysis
1.1). LOW QUALITY EVIDENCE (downgraded for risk of bias
and imprecision): (Summary of findings for themain comparison).
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Suspected catheter-related bloodstream infection (151
participants)
We were able to extract data from two studies that reported sus-
pected CRBSI (Benhamou 2002; Engervall 1995). Benhamou
2002 stated that no CVADs were removed due to suspicion of
CRBSI. In the Engervall 1995 trial 6/20 (30%) of CVADs were
removed in the once-weekly group and 4/19 (21%) in the twice-
weekly group due to suspected CRBSI (RR 0.70; 95% CI 0.23
to 2.10; Analysis 1.2). Both studies were at uncertain risk of bias
for allocation concealment, blinding of outcome assessment and
selective reporting. There was no clear evidence of a difference be-
tween the groups for this outcome. LOWQUALITY EVIDENCE
(downgraded for risk of bias and imprecision).
All-cause mortality (896 participants)
Three studies at uncertain risk of bias, included information about
all-cause mortality (Benhamou 2002; Engervall 1995; Timsit
2009). It was possible to combine the data from all these studies;
the studies were homogenous so the fixed-effect model was used
for data synthesis (I² = 0%). There was no clear difference in all-
cause mortality between longer (5-15 days) and shorter (2-5 days)
time intervals between dressing changes (RR 1.06; 95% CI 0.90
to 1.25; Analysis 1.3). LOWQUALITYEVIDENCE (downgraded
for risk of bias and imprecision): (Summary of findings for the
main comparison).
Secondary outcomes
Catheter-site infection (371 participants)
All five studies reported catheter-site infection but in a variety of
different ways. Benhamou 2002 and Rasero 2000 reported the
proportions of participants developing a catheter-site infection.
Engervall 1995 reported the rate of exit site infections per 100
CVAD days; Vokurka 2009 reported positive skin swabs and
Timsit 2009 reported rates of skin colonisation, Data from the
two studies (Benhamou 2002; Rasero 2000) that reported risk of
catheter-site infection in a similar way were pooled using a fixed
effect model (I2 = 0%). There was no clear evidence of a difference
in the risk of catheter-site infection rate between longer (5-15 days)
and shorter (2-5 days) time intervals between dressing changes
(RR 1.07; 95% CI 0.71 to 1.63; Analysis 1.4). LOW QUALITY
EVIDENCE (downgraded for risk of bias and imprecision).
Engervall 1995 reported 1.6 exit site infections per 100 CVAD
days (median, range 0 to 13.3) in the longer interval (less frequent)
group compared with 0 per 100 CVAD days (median, range 0 to
9.1) in the short interval (more frequent) group. Vokurka 2009
reported 13 positive skin swabs across both treatment groups but
did not report by group. We contacted the trialists of Timsit 2009
but they were unable to provide per patient data. The Timsit 2009
study reported catheter-site infection rates per catheter rather than
by patient in their published paper.
Consequently it remains unclear whether longer or shorter inter-
vals between dressing changes for CVADs influences the risk of
catheter-site infection.
Skin damage (1587 participants)
Skindamagewas reported in four studies (Benhamou 2002;Rasero
2000; Timsit 2009; Vokurka 2009). Data from two trials were
included in the forest plot (Benhamou 2002; Vokurka 2009). Re-
sults were highly heterogenous (I² = 78%), probably due to dif-
ferent scales being used to assess skin damage and dissimilar time
frames for assessment, so we did not pool the data. One of these
trials (Benhamou 2002) included only children and showed that
fewer participants in the longer interval group (8/56) scored grade
≥ 2 on the skin damage scale compared with 24/56 in the shorter
interval group (RR 0.33; 95% CI 0.16 to 0.68; P value 0.012;
Analysis 1.5). There was no clear evidence of a difference in rates
of skin damage between long and short intervals in adult patients
(Vokurka 2009) (RR 1.26; 95% CI 0.46 to 3.41; Analysis 1.5.
VERY LOWQUALITY EVIDENCE (downgraded for risk of bias,
imprecision and heterogeneity).
Two trials could not be included in the skin damage forest plot. In
the Rasero 2000 trial toxicity was graded on a 5-point scale, but
there were no reported differences between groups. We are unable
to use the data from the Timsit 2009 trial due to the 2 x 2 factorial
design.
Pain
Pain was assessed on a daily basis in two studies (Benhamou 2002;
Vokurka 2009). The maximum intensity of pain reported was
analysed. When data from the two studies were combined there
was no clear evidence of a difference in pain however this com-
parison is underpowered (RR 0.80; 95% CI 0.46 to 1.38; Analy-
sis 1.6; Benhamou 2002; Vokurka 2009). This was rated as LOW
QUALITY EVIDENCE (downgraded for risk of bias and impreci-
sion): (Summary of findings for the main comparison). The pain
classification systems used are detailed in the Characteristics of
included studies. The pain data were dichotomised on the basis of
a judgement that any pain experienced and reported by the patient
was clinically significant.
Quality of life
None of the studies reported quality of life.
Cost
Rasero 2000 reported the costs of nursing time and dressings and
stated that less frequent dressing changes would reduce costs by
400% in the tunnelled CVAD group and by 50% in the non-
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tunnelled CVAD group when compared to the standard practice
of changing dressings every second day. The monetary figures pre-
sented in the text and the table were different. Several attempts
have been made to contact the authors for clarification but with-
out success.
D I S C U S S I O N
Summary of main results
This systematic review included five RCTs (2277 participants) at
unclear or high risk of bias. We assessed the effects of prolonging
the frequency of dressing changes for CVADs on the incidence of
confirmed CRBSI, suspected CRBSI, all-cause mortality, CVAD
entry and exit site infection, skin damage, pain, quality of life and
cost. All studies used transparent polyurethane dressings, which are
often favoured over gauze dressings because they allow the catheter
site to bemonitored visually for signs of infection without removal
of the dressing. The longer intervals of dressing changes ranged
from 5 to 15 days and the shorter intervals from 2 to 5 days. It
was not possible to obtain data that would facilitate analysis at the
level of the patient rather than the catheter from two of the trial
authors. Rasero 2000 presented data for every dressing change and
Timsit 2009 reported data per catheter. One of the authors who
was contacted for additional information no longer had the data in
an accessible formdue to technological advances (Engervall 1995).
Most published literature in this field was ineligible for this review
as it compared the effect of different dressings on CRIs rather than
different frequencies of dressing change within the context of a
constant dressing type.
From the available data, we can draw no conclusions about the
incidence of confirmed or suspected CRBSI associated with differ-
ent intervals of dressing frequency. We used the CDC definition
of confirmed CRBSI (CDC 2002), which requires the CVAD to
be removed so that the tip can be quantitatively or semi-quantita-
tively cultured.Clinically this definition is impractical as it requires
the removal of the CVAD. Mermel 2009 offers a more practical
definition of two blood samples drawn (one from a catheter hub
and the other from a peripheral vein) that, when cultured, meet
CRBSI criteria for quantitative blood cultures or differential time
to positivity which would enable CVADs to remain in place until
the results of the blood cultures become available.
Similarily, neither benefits or harms of the intervention could be
demonstrated for all-cause mortality, CVAD entry and exit site
infection, pain, quality of life and cost. Most comparisons are
underpowered and therefore clinically important effects cannot be
excluded.
As highlighted in the Included studies section, each study used a
variety of antimicrobial solutions for skin decontamination. The
recent guidelines recommend using a > 0.5% chlorhexidine skin
preparation with 70% alcohol for skin decontamination or a 1%
to 2% tincture of iodine or povidone-iodine for sensitive skin
(Loveday 2014; INS 2011; IVNNZ 2012; O’Grady 2011). At
the time of these studies this preparation was not available. When
patients’ skin damage worsened in Benhamou 2002, Tegaderm
(3M) was no longer used and it is unclear how frequently the
Mefix tape or sterile gauze and tape dressing were changed. Skin
damage grade ≥ 2 occurred more frequently in the 4-day group,
which may have an effect upon the rates of skin infection.
It was not possible to provide an overall estimate of the effect
of changing dressings less frequently on skin damage. Data from
two small studies of limited quality reported contradictory results;
one trial favoured shorter times between dressing changes (two
dressing changes per week; Vokurka 2009), and the other favoured
longer times (up to 15 days; Benhamou 2002). In addition, the
Benhamou 2002 study was powered to detect a 30% improvement
in the rate of grade≥ 2 skin damage in the 15-day group, but only
17% of dressings in this group remained intact for this length of
time. In the Benhamou 2002 study, on average, the longer interval
dressings were in place for 8 days with no adverse events occurring
in either trial. Consequently, this raises the possibility of replacing
dressings onlywhen clinically indicated, especially in the paediatric
and neonatal population where skin is fragile. Patients receiving
radiotherapy, or those with existing sensitivities, may also benefit
from extending the time between dressing changes.
Overall completeness and applicability of
evidence
The primary and secondary outcomes of clinical interest included
confirmed and suspected CRBSI, all-cause mortality, catheter-site
infection, skin damage, pain, quality of life and cost, but these were
poorly reported and many results could not be extracted for this
review. These outcomes should be included in any future clinical
trials involving frequency of dressing changes.
The five studies included in this review were undertaken in acute
care settings in Europe. CVADs are usually placed in patients re-
quiring intensive care, treatment for malignancies and other pa-
tients requiring long-term treatment. Four of the studies recruited
participants with haematological malignancies or those undergo-
ing a bone marrow transplant. This population is immunocom-
promised due to their underlying disease or treatment, hence these
results may not be easily applied to patients with chronic health
problems or those being cared for in other settings.
Dressings and products for decontamination continue to evolve,
with new products constantly being developed and marketed. So,
although all of the studies in this reviewused transparent dressings,
older studies may have used products that are no longer available.
Other reviews have been published comparing different dressings.
The final limitation to the completeness and generalisability of
results is that all of the studies compared changing the frequency
of transparent polyurethane dressings only. Consequently, studies
16Frequency of dressing changes for central venous access devices on catheter-related infections (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
comparing the frequency of changing other types of dressings, such
as gauze and tape,may provide different results.Only one trial used
chlorhexidine impregnated sponges, which are now commonly
used, as part of the dressing regimen, but we could not extract
these data.
Quality of the evidence
Limitations in study design and implementation
Risk of bias was assessed according to six components: sequence
generation; allocation concealment; blinding; selective outcome
reporting, incomplete follow-up and other potential biases. The
risk of bias was difficult to assess due to poor reporting in most
of the studies (Figure 2; Figure 3). Only three studies provided
sufficient information to assess how the randomisation sequence
was generated; and two study authors we contacted described the
method used for allocation concealment. It would not be possible
for the participants and personnel to be blinded to the frequency of
dressing changes, but only one study blinded outcome assessments.
Two of the studies comprised 81% (2163/2675) of the total par-
ticipants (Benhamou 2002; Timsit 2009). These two studies cal-
culated the required sample size, used random-number generation
to allocate the sequence and used an intention-to-treat analysis.
However, neither was rated as being at low risk of bias for alloca-
tion concealment.
Protocol deviations were common in the treatment and control
arms. Dressings were changed early as they were soiled or not
intact. This issue reflects the reality of pragmatic research in clinical
settings and the importance of visual inspections of the dressing
to improve care and maintenance of the CVAD.
Indirectness of evidence
This reviewwas limited by a lack of uniformity in the experimental
and control groups. The frequency of the dressing changes over-
lapped at the outer limits of the longer (5 to 15 days ) and shorter
(2 to 5 days) intervals between dressings. Confirmed CRBSI was
reported in only one trial (Timsit 2009). These limitations restrict
confident decision making regarding the effect of frequency of
dressing changes on CRIs.
Unexplained heterogeneity or inconsistency of results
All-cause mortality and catheter-site infection were the only out-
comes that could be pooled using fixed-effect model for meta-
analysis. Pain was pooled using a random-effects model for meta-
analysis. It was not possible to pool the skin damage results due
to heterogeneity. Heterogeneity was generally due to differences
in populations and different scales and definitions that were used
for the various outcomes.
Imprecision of results
There was serious imprecision in all the results, even when meta-
analysis was undertaken, with wide confidence intervals due to the
small sample sizes. Consequently, results reflect a lack of evidence
of a difference rather than evidence of no difference (between
CVAD dressing change intervals). Further research is therefore
very likely to have an important impact on the confidence of the
estimates of effect for all of the measured outcomes.
Publication bias
Lack of information aboutmost of the important clinical outcomes
could suggest selective outcome reporting, but we were unable to
confirm this as only one study was registered with a trials registry.
Potential biases in the review process
The authors are confident that all studies meeting the inclusion
criteria were selected. The reference lists were handsearched and
only one additional title was found (Fessard 1994). The full pa-
per was requested from the author and from the journal, but to
date our requests remain unanswered. Clearly described proce-
dures were followed to prevent potential biases in the review pro-
cess. The methods used are transparent and reproducible. One of
the authors (CR) has given lectures for 3M and received an unre-
stricted research Grant from Centurion. No products from these
companies were included in this review.
Agreements and disagreements with other
studies or reviews
Zitella 2003 reviewed the literature concerning CVAD care
for patients undergoing bone marrow transplantation: only the
Engervall 1995 and Rasero 2000 studies were included in both
that review and ours. The Benhamou 2002 study was published
in the month that the Zitella 2003 review was accepted for pub-
lication and the other studies in our review were published af-
ter 2003. With regard to frequency of dressing changes, Zitella
2003 concluded firstly that the Engervall 1995 study showedmore
positive catheter tip cultures in the once-weekly group, but the
study was limited by a small sample size, and secondly that the
Rasero 2000 study showed no significant difference in skin coloni-
sation between the four groups. Overall, the authors concluded
that colonisation is a imperfect measure for CRBSI.
One of the excluded studies allocated participants to routine (every
72 hours) and non-routine (until removal of the CVAD) intervals
between dressing changes based upon the ward theywere admitted
to (cluster randomisation; Ishizuka 2011). There was a significant
inter-group difference in the duration of catheter dwell time (rou-
tine group 9.1 ± 0.5 days and non-routine group 11.9 ± 0.7 days).
There was a no significance in CRBSI between groups (13/241 in
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the routine group and 10/266 in the non-routine group). Kaplan-
Meier analysis and the log rank test revealed a significant differ-
ence in the period from insertion to the development of CRBSI
between the groups favouring the routine interval between dress-
ing changes (P value 0.026).
The Timsit 2009 RCT was subjected to a secondary analysis in
a later publication,Timsit 2012, which reported data on 1419
patients (3275 combined arterial catheters and CVADs) who had
their dressings replaced on the allocated third or seventh day versus
those with dressings replaced before any of the scheduled days.
They found that early dressing disruption (replacement) occurred
for 67% of scheduled dressings and was significantly associated
with increased skin colonisation, CRBSI and major CRI (CRBSI
or suspected CRBSI). For subclavian CVADs alone (n = 547), it
was reported that both percentage of dressings disrupted (P value
0.0043), and disruption of the final dressing (P value 0.0004)
were significantly associatedwith greater levels of skin colonisation
at CVAD removal. Those authors concluded that disruption of
dressings was common and an important risk factor for infection.
The wound and skin adhesive literature recognises that multiple
factors influence the degree of adhesion of the same product to
different people’s skin (Rippon 2007). It is also acknowledged that
trauma caused by repeated removal and application of adhesives
or adhesive tapes causes an erythematous reaction that affects the
barrier function of the skin (Cutting 2008; Hollingworth 2009).
Compromised barrier function becomes important when bacterial
overgrowth has been associated with occlusive dressings (Dykes
2007), such as the polyurethane dressings commonly used to se-
cure CVADs. However, whether polyurethane dressings are more
likely than other adhesive products to cause skin stripping remains
unclear (Cutting 2008; Dykes 2001). It is also unclear whether
there is an association between skin stripping and an increased in-
cidence of infection. However, damaged skin provides a potential
entry point for infection, so it makes sense to prevent the skin
damage occurring. The notion of preventing skin damage to avoid
CRI is supported by an infection control practice guideline, which
recommends not shaving insertion sites, to avoid micro-abrasions
that may encourage bacterial colonisation (Wilson 2006).
The counter argument to the skin stripping theory is that or-
ganisms originating from patients’ own skin are likely to be the
ones that cause many CRIs (Casey 2010; Elliott 1998; Gillies
2003; Maki 1997; Mermel 2000); these may be capable of mi-
grating from the skin surface along the outside of the catheter to
cause infection irrespective of skin damage (Wilson 2006). If skin
around the catheter site is disinfected regularly then colonisation
and CRBSI should be reduced. However, catheter-site infections
cannot be relied upon to identify or predict CRBSIs (Safdar 2002),
and can exist independently of a systemic infection (Walshe 2002).
Moreover, efforts to maintain skin integrity may assist in reducing
CRBSIs. While this may be true, the proportion of positive skin
cultures around the exit site has been found to be higher in the
presence of erythemawhen compared with healthy skin (Engervall
1995).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There are insufficient data to draw a conclusion regarding whether
the frequency of dressing changes influences CRBSI, suspected
CRBSI, all-cause mortality, catheter-site infection, skin damage in
adults, pain, quality of life or cost in people with central venous
access devices (CVAD). Although one small study suggested that
longer intervals between changesmay lower the risk of skin damage
in children, this was very low quality evidence. In the absence of
clear evidence of an increased risk associated with extending the
time between dressing changes, it is reasonable to base decisions
on patient preference and cost. CVAD sites should be inspected
on a daily basis to ensure dressings are clean and intact with no
signs of localised infection. Clinically indicated dressing changes
should occur if the dressing is soiled or not intact.
Implications for research
Future primary research on the frequency of CVAD dressing re-
placement should report confirmed CRBSI, suspected CRBSI and
all-cause mortality data. Researchers should use standardised def-
initions and measures and use per patient rather than per CVAD
or per dressing data to facilitate inclusion in future systematic re-
views and meta-analyses.To improve quality, future studies should
calculate sample sizes and report allocation concealment.
The link between skin colonisation and the incidence of CRBSI
raises an important question that should continue to be investi-
gated in future research; future research should report matched
positive skin and blood culture results obtained from individual
patients.
Economic analysis under the guidance of a health economist of-
fers comprehensive information about the costs and savings to
healthcare organisations and should be considered in future trials.
Engaging the views of patients and clinicians would be helpful, as
the frequency of dressing changes for CVADs is often guided by
patient tolerance.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Benhamou 2002
Methods Study design: Single centre RCT
Sample size calculation: Yes
ITT analysis: Yes
Ethics and informed consent: Kremlin-Bicetre, France
Registration number and name of registry: Not stated
Participants Population: Children with a malignancy, who were candidates for high dose chemo-
therapy and autologous or allogeneic bone marrow transplantation
Setting: Paediatric Bone Marrow Transplantation unit at the Gustave Roussy Institute,
Villejuif, France
Number: A total of 113 patients were randomised, 57 in the 15-day group and 56 in
the 4-day group. There was 1 post-randomisation exclusion, results were reported for
112 participants (56 in each group)
Age: 15-day group: median 5 years, range 1-22 years. 4-day group: median 7 years, range
2-19 years
Gender (male:female): 15-day group: 33:23. 4-day group: 25:31
Skin complexion: 15-day group: white 43/56; ’mat’ 10/56; black 3/56. 4-day group:
white 47/56, ’mat’ 6/56, black 3/56
Known allergies to dressings: Not stated
Known history of current BSI: Not stated
Inclusion criteria: Children with a malignancy, who were candidates for high dose che-
motherapy and autologous or allogeneic bone marrow transplant. A qualitative culture
of the skin at the catheter entry site was performed before randomisation: only children
with a negative culture for Staphyloccus epidermis were eligible
Exclusion criteria:Children were only included once in the trial. Those treated with the
busulfan-thiotepa conditioning regimen and those who already had grade≥ 2 cutaneous
toxicity at the catheter dressing site were not eligible
Interventions Aim: To compare the efficacy of 2 catheter dressing change frequencies (15-days versus
4-days)
Intervention: Dressing changed every 15 days
Control:Dressing changed every 4 days
Dressing protocol in both groups: “Three types of dressings were used according to
cutaneous toxicity; the adhesive transparent oxygen-permeable type (Tegaderm) for grade
0 and 1 (48/56; 85% in 15 day group and 32/56; 57% in the 4 day group); theMefix type
for grade 2 and 3 (7/56; 13% in the 15 day group and 23/56; 41% in the 4 day group)
; and the sterile gauze and tape (American style) dressing (Surgifix, Smith & Nephew,
Hull or Velpeau) for grade 4 (1/56; 2% in both the 15 and 4 day groups).
Dressings were changed by the nurse in charge of the patient, under sterile conditions:
the dressing was cautiously unstuck, the skin was cleaned with a sterile gauze and Hibidil
from the catheter entry point towards the periphery. A sterile gauze was then applied
under the dressing. The dressing had to cover the catheter entry point as well as the
catheter hub, and the upper limit of the extension line, whatever the dressing type.”
Duration of follow-up: Daily surveillance of the dressing and its periphery began on
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Benhamou 2002 (Continued)
the day of randomisation and was continued throughout hospitalisation
Numbers lost to follow-up: 1 child relapsed in the 15-day arm before HDC
Reason for CVAD insertion: HDC for autologous and allogeneic BMT
Method of CVAD insertion: “Catheters were all inserted (subclavian site) in the oper-
ating room under strict aseptic conditions. Physicians wore a cap, a mask, sterile gloves
and a gown. The insertion site was first qualitatively cultured and then prepared with
0.5% alcoholic chlorhexidine (Hibidil). The catheters were then inserted cutaneously
using the Seldinger technique, and tunnelled subcutaneously up to 10 cm on average
in order to allow rapid removal of the material if severe infectious complications were
suspected. In the absence of catheter-related adverse events, the device was left in place
until the patient was discharged from the bone marrow transplant unit.”
Anatomical location of CVAD: Subclavian site
Profession of CVAD inserter: Physician
Type of CVAD: Silastic catheters (Vygon)
Number of CVAD lumens: Single
Dwell time of CVAD: Not stated
Study dates: July 1990-April 1993
Outcomes Primary outcomes
CRBSI:Not included
Suspected CRBSI: Blood cultures were taken in the event of fever above 38.5°C and/
or signs of local infection
All-cause mortality: Reported mortality with causes
Secondary outcomes
Catheter-site infection: Bacteriological samples were taken from skin around the
catheter entry point, using plastic agar-coated slides (Unipath SA, Dardilly, France). All
colonies appearing within 48 h of incubation (37°C) were identified by the usual quali-
tative bacteriological procedures. Catheter entry site cultures were taken in the event of
fever above 38.5°C and/or signs of local infection
Skin damage: Skin toxicity at the catheter dressing site and its periphery. Skin toxicity
classified as grade 0: healthy skin; grade 1: slightly inflamed skin; grade 2: minor cu-
taneous lesions, dressing difficult to remove; grade 3: lesions reaching periphery of the
dressing; grade 4: cutaneous lesions to such and extent that the usual dressing could no
longer be used
Pain: Pain during and between dressing changes. Local pain (classified as none, moderate
or severe) during the dressing change and between dressing changes
Quality of life: Not included
Cost:Not included
Other outcomes reported in the trial
None
Inter-rater reliability: As dressing changes were performed by many different nurses,
the skin toxicity grading scale was tested during the 6 months preceding the trial so that
the different nursing teams could familiarise themselves with its use
Time points: Daily surveillance of the dressing and its periphery began on the day of
randomisation and was continued throughout hospitalisation. Whenever the dressing
was changed, the grade of skin toxicity was recorded
Notes
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Benhamou 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Evidence: “Computer-generated list was
used to allocate patients”
Comment: Adequate generation of the
randomisation sequence
Allocation concealment (selection bias) Unclear risk Evidence: Not stated in the trial report
Comment: Unable to judge
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Evidence: Not stated in the trial report
Comment:Not possible to blind the inter-
vention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Evidence: Not stated
Comment: Although it would have been
possible to blind outcome assessment, we
were unable to ascertain if this was done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Evidence: “One patient relapsed after ran-
domisation and did not receive high dose
chemotherapy (15-day group). The analy-
sis presented here thus concerns 56 patients
in each group.”
Comment:We do not believe that the loss
of 1 patient would have affected results
Selective reporting (reporting bias) Unclear risk Evidence: All planned outcomes reported
Comment:Nopublished protocol.We did
not request a copy of the protocol from the
trialist
Other bias High risk Evidence: Different dressings according to
skin damage
Comment: Different dressing protocols
may have introduced a bias
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Engervall 1995
Methods Study design: Single centre RCT
Sample size calculation: Not stated
ITT analysis: Not stated
Ethics and informed consent: Local ethics committee
Registration number and name of registry: Not stated
Participants Population: ”Patients with haematological malignancies and severe aplastic anaemia, in
need of a permanent central venous catheter.“
Setting: In-patient unit, Karolinska Hospital, Stockholm, Sweden
Number: The abstract states ”thirty-two consecutive patients with haematological dis-
orders . . . were randomly allocated to have their CVC bandages changed once (n=20)
or twice (n=19) a week. However, the ’Methods’ section of the paper states “Thirty-
one consecutive patients with haematological malignancies and one patient with severe
aplastic anaemia, in need of a permanent CVC, were allocated randomly to have their
CVC bandages changed, 16 in the once a week group and 16 in the twice a week group.
” In the results section, tables reported a total of 39 patients. It seems that 32 patients,
who had a total of 39 catheters were randomised
Age: Once-weekly group: median 46 years, range 18-85 years. Twice-weekly group:
median 50 years, range 22-84 years
Gender (male:female): Once-weekly group: 8:8. Twice-weekly group: 10:6
Skin complexion: Not stated
Known allergies to dressings: Not stated
Known history of current BSI: Not stated
Inclusion criteria: Not stated
Exclusion criteria: Not stated
Interventions Aim: To determine whether a reduction of dressings from twice to once weekly could
be performed safely in neutropenic patients
Intervention: Once-weekly dressing changes
Control: Twice-weekly dressing changes
Dressing protocol in both groups: “CVC changes were performed by the nurse respon-
sible for the patient at the ward. The catheter exit site was cleaned with 70% ethanol
and a transparent polyurethane dressing Tegaderm (3M) was applied to the area. No
other bandages were used, thus allowing the attending nurse to inspect the exit site daily.
The presence of erythema or other signs of infection was noted and documented. In the
presence of erythema, a gauze dressing moistened with 10% ethanol with aluminium
acetotartrate 10% was used. When erythema or other signs of infection had disappeared
the patient returned to the allocated changing interval.” Patients in the once-weekly
group had more extra dressings due to erythema compared to the twice-weekly group
(3%; 0-91% once-weekly group; 0%; 0-17% twice-weekly group; P value 0.08 expressed
as extra dressings days per CVAD days)
Deviation from planned dressing day: Not stated
Number of dressing changes during dwell time of CVAD: Not stated
Duration of follow-up:Daily skin assessments until 120 days post CVAD insertion
Numbers lost to follow-up: 12 patients died (Once-weekly group 6; Twice-weekly
group 6). 2 patients dislocated CVCs. 2 CVC tip cultures not obtained. 23 CVCs (14
Once-weekly group and 9 Twice-weekly group) for analysis
Reason for CVAD insertion: In need of a permanent CVC
Method of CVAD insertion: Inserted under aseptic conditions in an operating theatre
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Engervall 1995 (Continued)
Anatomical location ofCVAD:39 catheterswere inserted in 32patients’ internal jugular
(Once-weekly group 2; Twice-weekly group 2); external jugular (Once-weekly group 5;
Twice-weekly group 4); subclavian (Once-weekly group 13; Twice-weekly group 13) and
tunnelled subcutaneously for a distance of approximately 15 cm to an exit site at the
anterior of the thorax
Profession of CVAD inserter: Not stated
Type of CVAD: Silicone catheter
Number of CVAD lumens: Single
Dwell time of CVAD:Once-weekly group:median 39.5 days (range 8-114 days); Twice-
weekly group: median 46 days (range 13-120+ days)
Study dates: Not stated
Outcomes Primary outcomes
CRBSI:Not included.
Suspected CRBSI: Local catheter infections defined as > 15 CFU at catheter tip culture.
Positive blood culture defined as growth of bacteria in at least 1 sample from a peripheral
vein, and for coagulase-negative staphylococci growth in at least 2 of the 3 cultures taken.
The CVCwas removed aseptically. During granulocytopenia (< 0.5 x 109L−1) 3 separate
cultures were obtained (2 from a peripheral vein and 1 from the central line) for aerobic
and anaerobic cultures at start of fever (temperature > 38.0°C on 2 occasions with at
least a 4-h interval, or > 38.5°C on 1 occasion). Additional blood cultures were obtained
before change of antibiotic therapy in patients with a persistent fever
All-cause mortality: Reported
Secondary outcomes
Catheter-site infection: Skin cultures at exit site graded into 2 categories: < 10 CFU
per plate or ≥ 10 CFU per plate. CVC tip cultures
Skin damage:Dayswith erythema at the exit site, temperature > 38°C, antibiotic therapy
and the need for extra dressings. Erythema surrounding the exit site was graded into 2
categories: mild erythema, not requiring extra change of dressing or extensive erythema
or other signs of local infection requiring extra daily changes
Pain: Not included
Quality of life: Not included
Cost:Not included
Other outcomes reported in the trial
Number of catheters removed due to complications: The catheters were followed for the
first 120 days after insertion
Overall catheter survival time
Validity of measures: Not stated
Inter-rater reliability: CVC changes were performed by the nurse responsible for the
patient at the ward
Time points: Skin cultures samples for bacterial culture were obtained from the skin at
the exit site and from the skin next to the transparent dressing at the time of changing
the bandages
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Engervall 1995 (Continued)
Random sequence generation (selection
bias)
Unclear risk Evidence: Randomisation envelopes
mixed manually
Comment: This information was sought
from the author; it was not reported in the
publication
Allocation concealment (selection bias) Unclear risk Evidence: Randomisation envelopes
mixed manually
Comment: This information was sought
from the author; it was not reported in the
publication
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Evidence: Not stated
Comment:Not possible to blind the inter-
vention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Evidence: Not stated
Comment: Not possible
Incomplete outcome data (attrition bias)
All outcomes
Low risk Evidence: 6 participants died in each
group. Results analysed by catheter, not by
participant for most outcomes
Comment: Equal numbers died in each
group. Consequently we judged this ele-
ment to be at low risk of bias
Selective reporting (reporting bias) Unclear risk Evidence: All planned outcomes reported
Comment: Protocol not reviewed
Other bias High risk Evidence 1: The trial was stopped early,
following an interim analysis, when it be-
came clear that differences in the primary
outcome would not be found in the time
available for the study, this may or may not
indicate a potential bias
Comment 1: Based on unequal numbers
between the number of participant re-
cruited (32) and the numbers reported in
the tables (39), it seems as though results
were based on the number of catheters, not
the number of participants. Consequently,
there is, potentially, risk of a ’Unit of anal-
ysis’ error
Evidence 2: Different dressings according
to skin damage
Comment 2: Different dressing protocols
may have introduced a bias
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Rasero 2000
Methods Study design: Multi-centre RCT
Sample size calculation: Not stated
ITT analysis: Not stated
Ethics and informed consent: Ethical Committee of Azienda Ospedaliera Careggi,
Florence, Italy
Registration number and name of registry: Not stated
Participants Population: “Patients undergoing bone marrow transplantation (either autologous, al-
logeneic from sibling or unrelated donors, or recipients of autologous peripheral blood
stem cells).”
Setting: 7 Italian BMT centres
Number: “399 consecutive patients were enrolled: 230 patients with a tunnelled CVC:
10-day group 118/230 and 5-day group 112/230; 169 patients with a non-tunnelled
CVC: 5-day group 85/169 and 2-day group 84/169.”
Age: Not reported
Gender (male:female): Not reported
Skin complexion: Not reported
Known allergies to dressings: Not reported
Known history of current BSI: Not reported
Inclusion criteria: “Consecutive patients undergoing BMT (either autologous, allo-
geneic from sibling or unrelated donors, or recipients of autologous peripheral blood
stem cells).”
Exclusion criteria: “Patients with active cutaneous lesions at the site of CVC insertion
at the time of enrolment, patients with known allergy to polyurethane dressings and
patients with generalized dermatologic diseases.”
Interventions Aim: To compare 2 different time interval protocols for CVC dressing in order to assess
the effects on local infections and toxicity
Intervention: Tunnelled CVC 10-day dressing changes. Non-tunnelled CVC 5-day
dressing changes
Control: Tunnelled CVC 5-day dressing changes. Non-tunnelled CVC 2-day dressing
changes
Dressing protocol in both groups: “A detailed protocol for CVC dressing under con-
trolled sterile conditions was prepared, and all nurses involved in CVC maintenance
were asked to adhere strictly to it for the whole study period; it was the responsibility
of each Center’s coordinator to ensure the correct performance of the protocol. Sterile,
polyurethane transparent adherent dressings (Tegaderm, 3M) were used for the CVC
dressing.”
Number of dressing changes during dwell time of CVAD: Not stated
Duration of follow-up: Every dressing change until CVAD removal
Numbers lost to follow-up: Tunnelled CVC: 70/230. Non-tunnelled: 70/169
Reason for CVAD insertion: BMT
Method of CVAD insertion: Not stated
Anatomical location of CVAD: Not stated
Profession of CVAD inserter: Not stated
Type of CVAD: Not stated
Number of CVAD lumens: Not stated
Dwell time of CVAD: Not stated
Study dates: March 1996-October 1997
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Rasero 2000 (Continued)
Outcomes Primary outcomes
CRBSI:Not included
Suspected CRBSI:Not included
All-cause mortality: Not included
Secondary outcomes
Catheter-site infection:Cultures for bacterial and fungal agents were set up according to
established methodologies used in the microbiology department of each Center’s central
hospital laboratory
Skin damage: Severity of local skin toxicity directly attributable to the dressing procedure
itself. Cutaneous lesions were graded according to the ECOG scale. A specific data form
sheet was made available for recording ECOG grading in each patient for each dressing.
The following parameters were carefully checked at all dressing changes and at the time of
CVC removal: erythema, swelling, tenderness, induration, pain, pruritus, and purulence
Pain: Not included
Quality of life: Not included
Cost:Calculations were made using an exchange rate of USD 1 = ITL 1700. The actual
(net) cost of a nurse in an Italian public hospital was about USD 10/hour. Calculations
were based on the assumption that the mean hospital stay for an allogeneic patient
with a tunnelled CVC was about 40 days (corresponding to a total of 20 dressing
changes according to the standard protocol and to 4 changes in the new protocol); the
assumption for an autologous BMT recipient with a non-tunnelled CVC was about 20
days (corresponding to a total of 10 dressing changes in the standard protocol and 4 with
the new one). Median time per dressing was calculated from the scheduled time of PNR
(10 min), the Clock Survey from Azienda Ospedaliera Careggi, Florence (20 min), and
the time measured at the bed-side in the BMT Unit in Florence (13 min)
Other outcomes reported in the trial
None
Validity of measures: Not stated
Inter-rater reliability: A detailed protocol for CVC dressing under controlled sterile
conditions was prepared, and all nurses involved in CVC maintenance were asked to
adhere strictly to it for the whole study period; it was the responsibility of each centre’s
co-ordinator to ensure the correct performance of the protocol
Time points: Skin swabs were taken from the site of CVC insertion in all patients
enrolled in the study at the time of admission to the BMT Unit (basal sample) and later
on at 10-day intervals during the BMT procedure for the whole period of the patients’
stay in hospital
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Evidence: Not stated in the trial report
Comment: We were unable to judge the
adequacy of sequence generation
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Allocation concealment (selection bias) Unclear risk Evidence: Not stated
Comment: We were unable to judge the
adequacy of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Evidence: Not stated
Comment:Not possible to blind the inter-
vention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Evidence: Not stated
Comment: It would have been possible to
blind assessment of the study outcomes,
but this was not stated in the paper
Incomplete outcome data (attrition bias)
All outcomes
Low risk Evidence: All withdrawn patients ac-
counted for
Comment: All data complete
Selective reporting (reporting bias) Unclear risk Evidence: All planned outcomes reported
Comment: Protocol not reviewed
Other bias Unclear risk Evidence:
Comment: As no baseline data were pub-
lished, it was unclear if groups were
matched for important risk factors
Timsit 2009
Methods Study design: Multi-centre, 2 x 2 factorial, RCT
Sample size calculation: Yes
ITT analysis: Yes
Ethics and informed consent:Grenoble University Hospital Ethics Committee, France
Registration number and name of registry: NCT00417235 www.clinicaltrials.gov
Participants Population: “Patients expected to require an arterial catheter, central-vein catheter, or
both inserted for 48 hours or longer in ICU.”
Setting: 7 ICUs (2 medical, 2 surgical, 3 medical-surgical) in 3 university and 2 general
hospitals in France
Number: 1653 patients randomised: 416 in the 3-day standard dressing group; 412 in
the 3-day CHGIS group; 412 in the 7-day standard dressing group; 413 in the 7-day
CHGIS group
Age: Median 63 years (IQR 50-74)
Gender (male:female): 1052:584
Skin complexion: Not stated
Known allergies to dressings: Patients with a history of allergy to chlorhexidine or to
transparent dressings were excluded
Known history of current BSI: Not stated
Inclusion criteria: “Patients older than 18 years expected to require an arterial catheter,
central-vein catheter, or both inserted for 48 hours or longer in ICU. CVC inserted in
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the study ICU or immediately before by the anaesthetist in the emergency unit or in the
operating room. CVC inserted under maximal barrier precautions.”
Exclusion criteria: “Patients with a history of allergy to chlorhexidine or to transparent
dressings. Pulmonary arterial, haemodialysis and PICCs were not included. Antiseptic
and antibiotic impregnated CVCs were not included. CVC inserted under emergency
conditions. CVC not inserted under maximal barrier precautions.”
Interventions Aim: To assess superiority of CHGIS dressings (Biopatch, Ethicon, New Jersey, USA)
regarding the rate of major CRIs (clinical sepsis with or without bloodstream infection)
and non-inferiority (less than 3% colonisation-rate increase) of 7-day versus 3-day dress-
ing changes
Intervention: 7-day CHGIS group and 7-day standard dressing group
Control: 3-day CHGIS group and 3-day standard dressing group
Dressing protocol in both groups: “The same semipermeable transparent dressing
(Tegaderm; 3M Inc, St Paul, Minnisota) were used in all 4 treatment groups. The
dressing was changed 24 hours after catheter insertion (day 1) and then as randomised.
The alcohol-based povidone-iodine solution was used for skin antisepsis during dressing
changes. In theCHGIS group, the CHGIS dressing was applied to the entire skin surface
at and around the insertion site. The semitransparent dressing was then applied. A new
CHGIS was used at each dressing change.”
Deviation from planned dressing day: “Leakage or soiling prompted immediate dress-
ing change.”
Number of dressing changes during dwell time of CVAD: “Median 3 dressing changes
per catheter (IQR 1-5).”
Duration of follow-up:Until 48 h after ICU discharge
Numbers lost to follow-up:
7-day CHGIS group: 4 withdrew consent; 52 catheters/19 participants excluded from
per protocol analysis
7-day standard group: 3 withdrew consent; 57 catheters/22 participants excluded from
per protocol analysis
3-day CHGIS group: 4 withdrew consent; 54 catheters/29 participants excluded from
per protocol analysis
3-day standard group: 6 withdrew consent; 83 catheters/41 participants excluded from
per protocol analysis
Reason for CVAD insertion: ICU admission
Method of CVAD insertion: “All study centers followed French recommendations for
catheter insertion and care, which are similar to recommendations from the CDC. Max-
imal sterile barrier precautions (large sterile drape; surgical hand antisepsis; and mask,
cap, sterile gloves, and gown) were used at catheter insertion. The insertion site was
scrubbed with 4% aqueous povidone iodine solution (Betadine Scrub; Viatris Pharma-
ceuticals, Merignac, France), rinsed with sterile water, and dried with sterile gauze; an
alcohol-based antiseptic solution (5% povidone-iodine in 70% ethanol) (Betadine Al-
cohol-based Solution, Viatris) was then applied for at least 1 minutes, and sterile drapes
were placed around the site.”
Anatomical location of CVAD: Jugular 560/2051; subclavian 819/2051; femoral 672/
2051
Profession of CVAD inserter: Intensivist
Type of CVAD: Not stated
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Number of CVAD lumens: 0 lumens 37/2051; 2 lumens 209/2051; 3 lumens 1805/
2051
Dwell time of CVAD: “Median 6 days (IQR 4-10)”
Study dates: 20 December 2006-20 May 2008
Outcomes Primary outcomes
CRBSI: Major CRI (defined as catheter-related sepsis with or without bloodstream
infection
Catheter-related clinical sepsis without bloodstream infection defined as fever≥ 38.5°C
or ≤ 36.5°C; catheter tip culture yielding ≥ 10³ CFU/ml; pus at the insertion site or
resolution of clinical sepsis after catheter removal; absence of any other infectious focus
CRBSI was defined as a combination of ≥ 1 positive peripheral blood cultures sampled
immediately before or within 48 h after catheter removal; a quantitative catheter-tip
culture testing positive for the same micro-organism or a differential time to positivity
of blood cultures ≥ 2 h; no other infectious focus explaining the positive blood culture
result
Suspected CRBSI:Not included
All-cause mortality: Reported
Secondary outcomes
Catheter-site infection: Skin colonisation assessed by the semi-quantitative insertion-
site skin cultures at catheter removal
Skin damage: The condition of the skin was described on a standardised form by
the nurse in charge of the patients at each dressing change and at catheter removal,
using the International Contact Dermatitis Research Group system (0, normal skin; 1,
mild erythema; 2, red and slightly thickened skin; 3, intense redness and swelling with
coalesced large blisters or spreading reaction)
Pain: Not included
Quality of life: Not included
Cost:Not included
Other outcomes reported in the trial
None
Validity of measures: French (Timsit) and US (Mermel) guidelines
Inter-rater reliability: Not stated
Time points: Not stated
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Evidence: “The randomization schedule,
stratified by ICU, was developed using a
Web-based random-number generator to
select permuted blocks of 8 patients each.”
Comment: Adequate method for sequence
generation
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Allocation concealment (selection bias) Unclear risk Evidence: Not stated in the trial report
Comment: We were unable to judge the
adequacy of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Evidence: “The study was not blinded
for the investigators or ICU staff. Dou-
ble-blinding was not feasible, because vi-
sually identical sponges without chlorhexi-
dine were not available and the nurses had
to be informed of the dressing change in-
terval.”
Comment: Itwas not possible to undertake
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Evidence: “The study was blinded for the
microbiologists processing the skin and
catheter cultures and for the assessors. A
blinded procedure was used for the catheter
cultures. Independent assessors conducted
blind review of all suspected catheter infec-
tions.”
Comment: Adequate method for blinding
outcome assessor used
Incomplete outcome data (attrition bias)
All outcomes
Low risk Evidence: “1653 patients were enrolled,
but subsequently 17 withdrew consent to
participate, leaving 1636 available for in-
clusion in the ITT analysis.”
Comment: Similar numbers were reported
in both groups in the ITT analysis
Selective reporting (reporting bias) Low risk Evidence: Planned outcomes in methods
section and in the protocol (clinicaltrials.
gov) were reported in the paper
Comment:Althoughwewere unable to ex-
tract primary outcome data for this review
(because of the way it was reported) the
planned outcomes were reported in the pa-
per
Other bias Unclear risk Evidence: “The number needed to treat
with CHGIS dressings was 117 catheters
(95%CI, 86-1020). Treatment for 10 days
usually requires 3 dressings, each of which
costs US$6 (2007 $), and the cost of pre-
venting a single episode of major C-RI
can be estimated at $2106 (95%CI $1518-
$18360). The cost of managing a single
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case of major C-RI ranges from $8000 to
more than $28000, suggesting the CHGIS
dressings may be a cost saving.”
Comment: Uncertain of the NNTB. All
data presented per catheter rather than per
patient. Author contacted
Vokurka 2009
Methods Study design: Multicentre, RCT
Sample size calculation: Not stated
ITT analysis: Not stated
Ethics and informed consent: Ethical consent not stated. Informed consent obtained
Registration number and name of registry: Not stated
Participants Population: “Adults with acute myeloid leukaemia treated with intensive chemotherapy
containing cytosine-arabinoside (Ara-C) and anthracyclines.”
Setting: Hemato-Oncology Department, University Hospital
Number: Once-weekly (every 7 days) group: 39 participants. Twice-weekly (every 3-4
days) group: 42 participants
Age: Once-weekly group mean age 41.4 years (± 14.9). Twice-weekly group mean age
49.9 years (± 10.7)
Gender (male:female): Once-weekly group: 19:20. Twice-weekly group: 16:26
Skin complexion: Not stated
Known allergies to dressings: Patients were excluded
Known history of current BSI: Not stated
Inclusion criteria: “Adults with acute myeloid leukaemia treated with intensive chemo-
therapy containing cytosine-arabinoside (ara-c) and anthracyclines were included in the
observation.”
Exclusion criteria: “Patients with damaged skin at baseline, those allergic to disinfectant,
acrylate, or polyurethane, and patients with radiotherapy of the chest in their history
were excluded.”
Interventions Aim: To gain experience and to verify whether prolonging the dressing change interval
would really be of any benefit and be safe
Intervention: Dressings changed once weekly (every 7 days)
Control:Dressings changed twice weekly (every 3-4 days)
Dressing protocol in both groups: “Transparent polyurethane semi-permeable occlu-
sive dressings (Bioclusive, Johnson and Johnson). The dressing could be changed sooner
in case of an unstitched, loose, or soiled dressing, insertion-site inflammation, local cu-
taneous damage, in-site bleeding, or other significant (technical) reason.”
Deviation from planned dressing day: Once-weekly group: 58% dressing changes as
per protocol; Twice-weekly group: 80% dressing changes as per protocol
Number of dressing changes during dwell time of CVAD: “Once-weekly group: mean
number of occlusive dressing changes 4.5 (± 2.4). Twice-weekly group: mean number of
occlusive dressing changes 5.9 (± 2.5).”
Duration of follow-up: “Local cutaneous damage was assessed daily.”
Numbers lost to follow-up: All patients accounted for
Reason for CVAD insertion: Treatment with intensive chemotherapy
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Method of CVAD insertion: “Povidone-iodine was used for skin disinfection at the
time of CVC insertion and before any occlusive dressing application.”
Anatomical location of CVAD: Vena subclavia
Profession of CVAD inserter: Not stated
Type of CVAD: Non-tunnelled polyurethane CVCs
Number of CVAD lumens:Once-weekly group: 28 catheters with 1 lumen; 6 catheters
with 2 lumens; 8 catheters with 3 lumens. Twice-weekly group: 19 catheters with 1
lumen; 6 catheters with 2 lumens; 14 catheters with 3 lumens
Dwell time of CVAD: Not stated
Study dates: August 2003-August 2005
Outcomes Primary outcomes
CRBSI:Not included
Suspected CRBSI:Not included
All-cause mortality: Not included
Secondary outcomes
Catheter-site infection: Infection rate and insertion-site inflammation. The CVC in-
sertion-site inflammation was defined as local circular redness accompanied, in case of
larger reactions, with swelling and pain or palpitation in the area surrounding the point
of percutaneous insertion. Reported across both groups
Skin damage:Local cutaneous damagewas assessed daily using local institutional grading
(0: healthy skin, 1: erythema, 2: erythema with itching or dry desquamation, 3: moist
desquamation, exfoliation, 4: deep ulceration, necrosis)
Pain: Any pain or discomfort presented during the dressing change was evaluated by
patients using visual analogue scoring (VAS) ranging from0 to10 (0: nopain, 5:moderate
pain, 10: severe pain)
Quality of life: Not included
Cost:Not included
Other outcomes reported in the trial
Highest temperature and blood cultures for microbiological testing
Tolerance
Validity of measures: Not stated
Inter-rater reliability: Not stated
Time points: Daily assessment of skin. Skin swabs for microbiological testing were
obtained from the area around the CVC insertion-site on any dressing change before
local disinfection. The highest temperature was recorded on a daily basis and blood
cultures for microbiological testing were taken from the CVC on the first occurrence of
fever (> 38°C) and thereafter as indicated by the medical staff
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Evidence: “The patients were randomized
by GraphPad StatMate (GraphPad Soft-
ware Inc)”
Comment:Computer generated randomi-
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sation sequence
Allocation concealment (selection bias) Low risk Evidence: “As for our randomized trial
allocation, we used a Randomization PC
Software to allocate the trial patients into
the individual cohorts. We did not used
sealed envelopes.”
Comment: The evidence for this ’bias’ ele-
mentwas obtained from the trialist through
email contact
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Evidence: Not possible
Comment: Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Evidence:There was no information about
outcome assessor blinding in the report
Comment: Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Evidence: All of the enrolled patients were
accounted for in the results
Comment: An equal number of patients
(3) in each group were withdrawn due to
intolerance of the dressing Consequently,
we judged that this domain was at low risk
for bias
Selective reporting (reporting bias) Unclear risk Evidence: All planned outcomes reported
Comment: Protocol not reviewed
Other bias Low risk Evidence: None reported
Comment: As there were no ’other’ biases
reported, we judged this domain to be at
low risk
Abbreviations
BMT: bone marrow transplant
BSI: blood stream infection
CDC: Centers for Disease Control and Prevention
CFU: colony forming unit
CHGIS: chlorhexidine gluconate-impregnated sponge
CRBSI: catheter-related bloodstream infection
CRI: catheter-related infection
CVAD: central venous access device
CVC: central venous catheter
ECOG: Eastern Cooperative Oncology Group
h: hour(s)
HDC: high dose chemotherapy
ICU: intensive care unit
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IQR: inter-quartile range
ITT: intention-to-treat (analysis)
min: minute(s)
NNTB: number needed to treat for an additional beneficial outcome
PICC: peripherally inserted central catheter
PNR: patient nurse ratio
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bystricka 2004 Study protocol
Davidson 1986 Comparison of different dressing types not frequencies
Dickerson 1989 Letter to the editor (comment on a study comparing two types of dressings)
Hagerstrom 1994 Conference abstract related to dressing methods - unrelated to timing
Ishizuka 2011 The wards involved were randomly allocated, not the patients
Lucas 1996 Comparison of different dressing types not frequencies
Powell 1985 Co-interventions (frequency of administration set replacement) were different between different arms of the
study
Samsoondar 1985 Co-interventions (frequency of administration set replacement) were different between different arms of the
study
Quasi-randomisation
Young 1988 Co-interventions (frequency of administration set replacement) were different between different arms of the
study
Zitella 2003 Systematic literature review of central venous catheter site care for blood and marrow transplant recipients
Characteristics of studies awaiting assessment [ordered by study ID]
Fessard 1994
Methods Unknown
Participants Paediatrics
Interventions Frequency of dressing changes
37Frequency of dressing changes for central venous access devices on catheter-related infections (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fessard 1994 (Continued)
Outcomes Unknown
Notes Prospective randomised trial to study the best time interval between catheter dressing: Study performed by the nurses
of paediatric transplantation unit. Title found in a reference list. Awaiting paper from publishers
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D A T A A N D A N A L Y S E S
Comparison 1. Longer interval (5-15 days) (intervention) versus shorter interval (2-5 days) (control)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter related blood stream
infection
1 995 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [0.40, 4.98]
2 Suspected catheter related blood
stream infection
2 151 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.23, 2.10]
3 All-cause mortality 3 896 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.90, 1.25]
4 Catheter-site infection 2 371 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.71, 1.63]
5 Skin damage 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Pain 2 193 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.46, 1.38]
A D D I T I O N A L T A B L E S
Table 1. Blinding of participants and personnel (performance bias)
Benhamou 2002 Engervall 1995 Rasero 2000 Timsit 2009 Vokurka 2009
CRBSI Not applicable Not applicable Not applicable High risk Not applicable
Suspected CRBSI High risk High risk Not applicable Not applicable Not applicable
All-cause mortality Low risk Low risk Not applicable Low risk Not applicable
Catheter-site infec-
tion
High risk High risk High risk High risk High risk
Skin damage High risk Not applicable High risk High risk High risk
Pain HIgh risk Not applicable Not applicable Not applicable High risk
Quality of life Not applicable Not applicable Not applicable Not applicable Not applicable
Cost Not applicable Not applicable High risk Not applicable Not applicable
Table 2. Blinding of outcome assessment (detection bias)
Benhamou 2002 Engervall 1995 Rasero 2000 Timsit 2009 Vokurka 2009
CRBSI Not applicable Not applicable Not applicable Low risk Not applicable
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Table 2. Blinding of outcome assessment (detection bias) (Continued)
Suspected CRBSI Unclear risk Unclear risk Not applicable Not applicable Not applicable
All-cause mortality Low risk Low risk Not applicable Low risk Not applicable
Catheter-site infec-
tion
Unclear risk Unclear risk Unclear risk Low risk Unclear risk
Skin damage Unclear risk Not applicable Unclear risk Unclear risk Unclear risk
Pain Unclear risk Not applicable Not applicable Not applicable Unclear risk
Quality of life Not applicable Not applicable Not applicable Not applicable Not applicable
Cost Not applicable Not applicable Unclear risk Not applicable Not applicable
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